Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 379-387

  Carducci, Michael A ^a   Nelson, Joel B ^a   Chan Tack, Kirk M ^a   Ayyagari, Sujatha R ^a   Sweatt, William H ^a   Campbell, Pearl A ^a   Nelson, William G ^a   Simons, Jonathan W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; GLYCOPROTEIN P; PHENYLACETIC ACID; PHENYLBUTYRIC ACID; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTYRIC ACID; DNA; HUMANS; MALE; PHENYLACETATES; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; RATS; TUMOR CELLS, CULTURED;

EID: 0029962932     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Samid, D., Shack, S., and Sherman, L. T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992
2. Samid, D., Ram, Z., Hudgins, W. R., Shack, S., Liu, L., Walbridge, S., Oldfield, E. H., and Myers, C. E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1994.
3. Samid, D., Shack, S., and Myers, C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. C. I., 91: 2288-2295, 1993.
4. Samid, D., Yeh, A., and Prasanna, P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood, 80: 1576-1581, 1992.
5. Liu, L , Shack, S., Stetler-Stevenson, W. G., Hudgins, W. R., and Samid, D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylburyrate. J. Invest. Dermatol., 103: 335-340, 1994.
6. Wada, R., Han, G., Moore, T., Samid, D., and Sidell, N. Effects of phenylacetate and its interaction with retinoic acid on human neuroblasloma differentiation. Proc. Am. Assoc. Cancer Res., 35: 419, 1994.
7. Fibach, E., Prasanna, P., Rodgers, G., and Samid, D. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood, 82: 2203-2209, 1993.
8. Dover, G. J., Brusilow, S. W., and Charache, S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood, 84: 339-343, 1994.
9. Brusilow, S. W., Danney, M., Waber, L. J , Batshaw, M., Burton, B., Levitsky, L., Roth, K., McKeethren, C., and Ward, J. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N. Engl. J. Med., 310: 1630-1634, 1984.
10. Brusilow, S. W. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr. Res., 29: 147-150, 1991.
11. Mitchell, R. B., Wagner, J E., Karp, J. E , Watson, A. J., Brusilow, S. W., Przepiorka, D., Storb, R., Santos, G. W., Burke, P. J., and Saral, R. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am. J. Med. 85: 662-667, 1988.
12. Knoop, F. Der abbau aromatischer fettsaure tier korper. Beitr. Chem. Pysiol. Pathol., 6: 105-162, 1905.
13. Brusilow, S. W., Tinker, J., and Batshaw, M. L. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science (Washington DC), 207: 659-661, 1980.
14. Piscitelli, S. C., Thibault, A., Figg, W. G., Tompkins, A., Headlee, D , Liebermann, R., Samid, D., and Myers, C. E. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine J Clin. Pharmacol., 35: 368-373, 1995.
15. Wood, C. G., Lee, C , Grayhack, J. T., and Kozlowski, J. M. Phenylacetate and phenylbutyrate promote cellular differentiation in human prostate cancer systems. Proc. Am. Assoc. Cancer Res., 35: 403, 1994.
16. Augeron, C., and Laboisse, C. L. Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res., 44: 3961-3963, 1984.
17. Hague, A., Manning, A. M., Hanlon, K. A., Huschtscha, L. I., Hart, D., and Paraskeva, C. Sodium butyrate induces apoptosis in human colonic tumor cell lines in a p53 independent pathway: implications for the possible role of dietary fibre in the prevention of large bowel cancer. Int. J. Cancer, 55: 498-505, 1993.
18. Barnard, J. A., and Warwick, G. Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth. & Differ., 4: 495-501, 1993.
19. Burton, K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J , 62: 315-323, 1956.
20. Wyllie, A. H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (Lond.), 284: 555-556, 1980
21. Colotta, F., Re, F., Polentarutti, N., Sozzani, S., and Mantovani, A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood, 80: 2012-2020, 1992.
22. Hanaoka, K , Fujita, N., Lee, S., Seimiya, H., Maito, M., and Tsuruo, T. Involvement of CD45 in adhesion and suppression of apoptosis of mouse malignant T-lymphoma cells. Cancer Res., 55: 2186-2190, 1995.
23. Carroll, A. G., Voeller, G. J., Sugars, L., and Gelmann, E. P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 23: 123-134, 1993.
24. Isaacs, W. B., Carter, B. S., and Ewing, C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 5/1 4716-4720, 1991.
25. Isaacs, J. T., Landmu, P. I., Berges, R., Martikainen, P., Kyprianou, N., and English, H. F. Androgen regulation of programmed cell death of normal and malignant prostatic cells. J. Androl., 13: 455-484, 1992.
26. Isaacs, J. T., Isaacs, W. B., Feitz, W. F. G., and Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-281, 1986.
27. Isaacs, J. T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate, 5: 1-18, 1984.
28. Isaacs, J. T. Antagonistic effect of androgen on prostatic cell death. Prostate, 5: 545-558, 1984.
29. Liu, L , Bar-Ner, M., Weber, J., Damelpour, D., Qian, S. W., Shearer, G. M., and Samid, D Enhancement of tumor immunogenicity by phenylacetate and derivatives: changes in surface antigens and tumor derived immunosuppressive factors Proc. Am. Assoc. Cancer Res., 35: 481, 1994.
30. Hudgins, W. R , Pineau, T., Sher, T., Gonzales, F. J., Myers, C. E., and Samid, D. Anticancer activity of phenylacetate and related aromatic fatty acids: correlation with lipophilicity and capacity to activate nuclear receptor. Proc. Am. Assoc. Cancer Res., 35: 391, 1994.
31. Samid, D., Hudgins, W. R., Shack, S., Miller, A. C , Liu, L., Prasanna, P., Walls, R., and Myers, C. E. Phenylacetate and derivatives: simple compounds with complex antitumor activities. Proc. Am. Assoc. Cancer Res., 35: 408, 1994.
32. Malvilio, F., Kreider, B. L., Valtieri, M., Naso, G., Shirsat, N , Venturelli, D., Reddy, E. P., and Rovera, G. Alteration of growth and differentiation factors response by Kirsten and Harvey sarcoma viruses in the IL-3-dependent murine hematopoietic cell line 32D C13. Oncogene, 4, 301-308, 1989.
33. Norton, V. G., Imai, B. S., Yau, P., and Bradbury, E. M. Histone acetylation reduces nucleosome core particle linking number change. Cell , 57: 449-457, 1989.
34. deFazio, A , Chiew, Y. E., Donoghue, C., Lee., C., and Sutherland, R. L. Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines. J. Biol. Chem., 267: 18008-18012, 1992.
35. Heerdt, B. G., Houston, M. A., and Augenlicht, L. H. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res., 54, 3288-3294, 1994.
36. Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W. S., Kim, W. Y., and Simons, J. W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45: 542-549, 1995.
37. Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., and Simons, J. W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med., 1: 944-949, 1995.
38. Figg, W. D., Walls, R. G., Cooper, M. R., Thibault, A., Sartor, O., McCall, N. A., Myers, C E., and Samid, D. In vitro antitumor effect of hydroxyurea on hormone refractory prostate cancer cells and its potentiation by phenylbutyrate. Anticancer Drugs, 5: 336-342, 1994.